Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

L. Zheng



Author of

  • +

    P2.02 - Poster Session with Presenters Present (ID 462)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Locally Advanced NSCLC
    • Presentations: 1
    • +

      P2.02-056 - FGFR Gene Mutation is an Independent Prognostic Factor in Squamous Non-Small Cell Lung Cancer, and Associated with Lymph Node Metastasis (ID 4308)

      14:30 - 14:30  |  Author(s): L. Zheng

      • Abstract
      • Slides

      Background:
      Targeting FGFRs is one of the most promising therapeutic strategies in squamous non-small cell lung cancer (SQCC). However, different FGFR genomic aberrations can be associated with distinct biological characteristics that result in different clinical outcomes or therapeutic consequences. Currently, the full spectrum of FGFR gene aberrations and their clinical significance in SQCC have not been comprehensively studied.

      Methods:
      Next-generation sequencing was used to investigate FGFR gene mutations in 143 patients with SQCC who had not been treated with chemotherapy or radiotherapy prior to surgery.

      Results:
      FGFR gene mutations were identified in 24 cases, resulting in an overall frequency of 16.9%. Among the mutations, 7% (10/143) were somatic mutations, and 9.8% (14/143) germline mutations. FGFR mutations were significantly associated with an increased risk of lymph node metastasis (adjusted OR = 4.75, 95% CI = 1.78-12.7, P = 0.002). SQCC patients with a FGFR somatic mutation had shorter OS (overall survival, log rank P = 0.008) and DFS (disease-free survival，log rank P = 0.006) compared with those without an FGFR mutation. The multivariate analysis confirmed that a somatic mutation was an independent poor prognostic factor for OS (HR: 2.76, 95% CI: 1.05-7.27, P = 0.04) and was associated with reduced DFS (HR: 2.22, 95% CI: 0.97-5.07, P = 0.06). Figure 1



      Conclusion:
      FGFR mutation may increase the risk of lymph node metastasis in patients with SQCC. FGFR somatic mutation could be a useful biomarker for predicting poor clinical outcome in SQCC.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.